Newswise — SEATTLE – Investigators at Fred Hutchinson Cancer Research Center will share new research findings at the annual meeting of the American Society of Clinical Oncology, or ASCO, which is being held May 29–June 2 in Chicago.
New findings by Dr. Amanda Phipps regarding alcohol and colorectal cancer prognosis will be presented on Saturday.
On Sunday, Dr. Sunil Hingorani, will present the interim results of a clinical trial testing a new therapy for pancreatic cancer patients.
Dr. Jean McDougall will share, via a Monday poster session, new findings regarding costs and resource utilization associated with skeletal events, or complications, in patients with prostate cancer that has spread to the bones.
On Monday, Dr. Cameron Turtle will present data from an ongoing, early-stage clinical trial indicating that a first-of-its-kind immunotherapy is safe and feasible in certain patients with particular forms of acute lymphoblastic leukemia, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance will be addressed by Dr. Joshua Roth as he presents his findings at ASCO on Monday.
A full list of Fred Hutch researchers presenting at ASCO follows.
Oral Abstract Sessions
Amanda Phipps, M.D.Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance).
Session: Cancer Prevention, Genetics, and EpidemiologyTime: Saturday May 30, 1:15 PM - 4:15 PMLocation: S100bcAbstract Number: 1508
Sunil Hingorani, M.D., Ph.D.High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.
Session: Gastrointestinal (Noncolorectal) CancerTime: Sunday May 31, 8:00 AM - 11:00 AMLocation: E Hall D2Abstract Number: 4006
Cameron Turtle, M.B.B.S., Ph.D.Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.
Session: Developmental Therapeutics—ImmunotherapyTime: Monday June 1, 1:15 PM - 4:15 PMLocation: S406Abstract Number: 3006
Ajay Gopal, M.D.A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.
Session: Developmental Therapeutics—ImmunotherapyTime: Monday June 1, 1:15 PM - 4:15 PMLocation: S406Abstract Number: 3004
Poster Sessions
Shailender BhatiaPilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC).
Session: Developmental Therapeutics—ImmunotherapyTime: Saturday May 30, 8:00 AM to 11:30 AMLocation: S Hall APoster Board #409Abstract Number: 3083
Elahe Mostaghel, M.D., Ph.D.Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).Session: Genitourinary (Prostate) Cancer
Time: Saturday May 30, 1:15 PM - 4:45 PMLocation: S Hall APoster Board #5Abstract Number: 5013
Hannah RichardsA functional kinome screen to identify pathways of anthracycline resistance in patient-derived breast cancer cells.
Session: Tumor BiologyTime: Sunday May 31, 8:00 AM - 11:30 AMLocation: S Hall APoster Board #306Abstract Number: 11092
Scott Ramsey, M.D., Ph.D.Quality of life EQ-5D results from the AETHERA trial: A phase III study of brentuximab vedotin consolidation following autologous stem cell transplant for HL.
Session: Health Services Research and Quality of CareTime: Monday June 1, 1:15 PM - 4:15 PMLocation: S Hall APoster Board #125Abstract Number: 6568
Jean McDougall, Ph.D.Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones.
Session: Health Services Research and Quality of CareType: Poster SessionTime: Monday June 1, 1:15 PM - 4:45 PMLocation: S Hall APoster Board #169Abstract Number: 6612
Joshua Roth, Ph.D., M.H.A.Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance.
Session: Health Services Research and Quality of CareTime: Monday June 1, 1:15 PM - 4:45 PMLocation: S Hall APoster Board #173Abstract Number: 6616
# # #
40 YEARS OF CURES 1975-2015
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.
MEDIA CONTACTMichael NankMedia Relations Manager[email protected]206.667.6906
RSS